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I. Introduction
The goal of this research project is to better understand the tumor suppressive and apoptotic functions of the p53 tumor suppressor protein. As the p53 tumor suppressor gene is mutated or inactivated in up to 30% of breast cancers, understanding how this tumor suppressor gene functions to suppress breast cancer is an important goal. Our research in this application initially proposed creating recombinant viruses that selectively replicated in tumor cells with inactivated or mutant versions of p53. This work led to our surprising discovery that p53 has a transcription-independent mechanism for programmed cell death. Further, this direct, transcription-independent function of p53 is influenced by a common polymorphism in p53, at codon 72. Specifically, we have found that the arginine 72 form of p53 (R72) has over 15-fold increased ability to induce programmed cell death than the proline 72 (P72) form. Significantly, a retrovirus that encodes the R72 form of p53 also has increased ability to target and destroy tumor cells, relative to a retrovirus that expresses equivalent levels of the P72 protein. These studies led to our discovery using mass spectrometry that the R72 form of p53 interacts directly with the pro-apoptotic protein BAK. Research from this proposal has directly led to 3 publications in outstanding peer-reviewed journals, Nature Cell Biology, J Natl Cancer Inst, and Cell Cycle (reprints included in the Appendix). More importantly, the research accomplished by this proposal has the immediate potential to create novel avenues for effecting breast cancer treatment, and for understanding inter-individual differences in cancer risk and treatment efficacy.
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II. Body
A. Overview of Progress, Year 3:
Year 3 had two goals. The first was the completion of a selectively-replicating adenovirus in which the adenoviral ElA gene is controlled by the p53-repressible survivin promoter. Because such selectively replicating adenoviruses were being rapidly generated by other laboratories, and several of these showed minimal improvement over conventional chemotherapeutic modalities', we opted instead for our proposed alternate approach, which was to create adenoviruses that express either the R72 or P72 forms of p53. We proposed to create such viruses, and compare their ability to induce programmed cell death in infected cells. We created the R72 and P72 forms of p53 using the AdEasy vector system from Stratagene. These viruses infect both murine and human cell lines with high efficiency. Our data reproducibly indicate that the adenovirus expressing R72 (Ad-R72) has over 10-fold increased ability to induce programmed cell death, compared to the adenovirus expressing P72 (Ad-P72). These findings suggest that gene therapy with p53 vectors should be used with the R72 version of this protein, instead of the P72 version, which is currently used.
The second goal of year 3 was to elucidate the mechanism underlying transcriptionindependent cell death by the R72 form of p53. We previously showed in year 2 that the R72 form of p53 induces apoptosis more effectively than P72 because R72 traffics more efficiently to mitochondria, where p53 binds and oligomerizes BAK (Leu et al., Nat Cell Biology; manuscript included in the Appendix). In order to understand this more fully, we narrowed down the region of p53 that is necessary and sufficient to oligomerize BAK to a 20-amino acid peptide from amino acids 270-290. Notably, this region has significant homology to a BH3 domain (BCL2 homology 3, see Figure 2 ). BH3 domains are known to be capable of directly inducing BAK oligomerization and programmed cell death. These efforts led to our modeling of the p53-BAK interaction using molecular modeling programs. These efforts led to the identification of key residues in p53 responsible for contacting BAK. We fully expect that these efforts will lead to the creation of peptidomimetics with the ability to bind and oligomerize BAK, and subsequently lead to cell death.
B. Detailed Progress:
Task 3. Creation of recombinant adenoviruses expressing either the P72, or R72, forms of p53, and compare these for cell killing ability.
We created the R72 and P72 forms of p53 using the AdEasy vector system from Stratagene. Virus was purified using cesium chloride gradients, and used to infect NIH 3T3 and MCF-7 cells at a multiplicity of infection (m.o.i.) of 1 or 10, and compared to the Ad-GFP control. Infection with the Ad-GFP control at an m.o.i of 10 indicated that 100% of NIH 3T3 cells were infected (not shown). Significantly, cells infected with either Ad-P72, Ad-R72, or Ad-GFP were monitored 24 hours after infection for apoptosis using the Annexin V assay and the Guava Personal Cytometer. These analyses DAMD-17-02- reproducibly indicated that the Ad-R72 construct induced up to 10-fold more cell death, compared to Ad-P72, despite the fact that nearly equal levels of both proteins were expressed (see Figure 1 ). Studies are underway to determine if this increase in cell killing by Ad-R72 is true for other breast carcinoma cell lines as well. We are also testing the ability of these adenovirally-expressed p53 proteins to bind and oligomerize BAK in infected cells. Task 3: Determine the mechanism for cell death of adenovirally-expressed p53.
We recently reported that p53 binds to the mitochondrial protein BAK, and can directly oligomerize BAK and induce cytochrome c release and cell death 2 ' 3 . In efforts to better understand this activity, we chose to delineate the region of p53 that is necessary and sufficient for interaction with, and oligomerization of, BAK. Using GST fusion proteins containing different portions of p53, and in vitro BAK oligomerization assays, we narrowed down the region of p53 resposnible for binding and oligomerizing BAK to amino acids 270-290 of this protein (not shown). Notably, this region contains significant homology to the BH3 domains of other Bcl2 family members (see Figure 2) .
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HAK TILEI-- GR2L 6 D p53 helix RE Figure 2 . Alignment of the p53 helix from amino acids 278-289 to the BH3 domains from BAK and BAD. Asterisks mark key residues in the alignment.
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Molecular modeling of the p53-BAK interaction.
In collaboration with the Molecular Modeling Core Facility at Fox Chase Cancer Center, we recently modeled the interaction of the p53 "BH3-1ike" domain with BAK (see Figure 3) . This modeling revealed extensive charge-charge interactions between amino acids in p513 and BAK, and highlighted interactions between p 5 3 residues 280 and 282 with MURPHY, M.E. DAMD-17-02-1-0383 BAK serine 117, and BAK aspartic and glutamic acid residues 85 and 92, respectively. Validation of this model was provided by our finding that mutation of either p53 arginine 280 or 282 to aspartic acid inhibited the ability of p53 to oligomerize BAK (see Figure  4) . Interestingly, we also found that mutation of residue 282 to tryptophan, which occurs in a significant percent of human cancers including breast cancers, also abrogates the ability of p53 to oligomerize BAK. We are currently expanding our efforts to validate this model. We plan to extend these studies to test the ability of this 20 amino acid peptide to oligomerize BAK, and induce cell death, in cultured breast carcinoma cell lines.
GST-p53
GST-p53 (160-318) (160-318) Figure 4 . 
III. Key Research Accomplishments
-Creation of adenovirus vectors that express the arginine 72 polymorphic variant of p53, as well as the proline 72 variant. -Demonstration that the Ad-R72 virus induces 10-fold increased cell death than the Ad-P72 virus, despite equal levels of protein expressed. -Molecular modeling of the p53-BAK interaction, which we have shown is critical for transcription-independent programmed cell death by p53. -Validation of the p53-BAK molecular model, with the demonstration that mutation of two predicted key residues eliminates the ability of p53 to oligomerize BAK. Viruses:
1. The Ad-R72 and Ad-P72 adenoviruses.
V. Conclusions
-We have shown that the P72 form of p53, which is currently being used in all gene therapy efforts utilizing the p53 tumor suppressor protein, is a significantly poorer inducer of apoptosis than the R72 form of p53. -We have shown that the R72 form of p53 induces cell death better due to enhanced mitochondrial localization of this form of p53. -Once at the mitochondria, we used mass spectrometry analysis to identify the BCL2-family member BAK as a key p53-interacting protein. - tumor-selective promoter may also be useful in tumor-prone Background: Survivin, a member of the IAP (inhibitor of transgenic mice by activating the expression of a marker gene at apoptosis) gene family, appears to be overexpressed in com-the initiation of oncogenesis. In this study, we used transfection mon cancers but not in corresponding normal adult tissues. experiments to examine whether 1092 base pairs of the 5' upTo investigate whether the survivin promoter controls can-stream regulatory sequence of the human survivin gene could cer cell-specific gene expression, we determined whether the control the expression of a reporter gene in cancer cell lines survivin gene promoter could regulate reporter gene expres-derived from tumors of the uterine cervix, breast, ovary, lung, sion in cancer cell lines and xenografts. Methods: Survivin and colon. We also evaluated the activity of the survivin proprotein levels were determined in human and murine cancer moter in a cancer cell line in vivo as a xenograft. cell lines and in normal tissues of adult C57BL/6 mice by MATERIALS AND METHODS Western blot analysis. A reporter construct in which a portion of the survivin gene promoter was used to drive tran-Cell Lines and Cell Culture scription of a human secreted alkaline phosphatase (SEAP)
The following human cancer cell lines (and their tissue of gene was transiently transfected into cancer cells, and pro-origin) were used in this study: A2780, OVCAR3, OVCAR5, moter activity was extrapolated from SEAP activity. A2780 OVCAR8, OVCAR10, SKOV3, PEO1, and UPN251 (ovary); human ovarian cancer cells were transfected with this con-HT29 (colon); MCF7 (breast); H1299 (lung); and HeLa (uterus). struct, and stable transfectants were injected into the intra-ROSE-TAg is a tumorigenic cell line derived from Fisher 344 bursal ovarian space of immunodeficient mice. Tumor rat ovarian surface epithelial (ROSE) cells transformed with growth was monitored, and plasma SEAP levels were used as simian virus 40 (SV40) large T antigen (TAg) in vitro. NuTul9 a measure of survivin promoter activity in vivo. Results: Sur-and NuTu26 are spontaneously transformed cell lines derived vivin protein was detected in all cancer cell lines examined from Fisher 344 ROSE cells (7) . IG10 and IF5 are spontaneously but not in most normal adult mouse tissues. After transfec-transformed mouse ovarian surface epithelial (MOSE) cell lines tion, the survivin promoter was more active in all cancer cell (8) . Mc6 is a mammary cancer cell line derived from a mamlines than in normal ovarian surface epithelial cells or mouse mary tumor of a mammary tumor-prone C3 (1)/TAg transgenic 3T3 cells. After 0.8 x 106 stable transfectant cells were in-mouse line, and Pr14 is a prostate cancer cell line derived from jected into the intrabursal cavity of mouse ovaries, plasma a prostate tumor of a prostate cancer-prone line of C3 (1)/TAg SEAP activity was detected within 24 hours, and the activity transgenic mice (9, 10) . Normal MOSE cells were isolated from increased with time and tumor growth. Conclusion: Trans-the ovaries of C57BL/6 adult mice (8) and used for up to three fection experiments indicate that survivin protein expression passages. Normal ROSE cells were isolated from the ovaries of in cancer tissue appears to be regulated, at least in part, Fisher 344 rats (7) and used for up to five passages. Normal transcriptionally. Thus, the survivin promoter may be useful human ovarian surface epithelial (HOSE) cells were derived in controlling gene expression in cancer cells. [J Natl Cancer from normal human ovaries as previously described (11) . NIH Inst 2002; 94:522-8] 3T3 is an immortalized, nontumorigenic mouse fibroblast cell line. All cell lines were maintained at 37 °C in a humidified incubator with an atmosphere of 5% C0 2 /95% air. HOSE, Members of the inhibitors of apoptosis (IAP) gene family A2780, OVCAR3, OVCAR5, OVCAR8, OVCAR10, SKOV3, may play important roles in the survival of cancer cells and the PEO1, UPN251, ROSE-TAg, NuTu19, NuTu26, MCF7, and progression of malignancies. The first IAP isolated was the normal ROSE cells were cultured in RPMI 1640 medium product of a baculovirus gene. Other members of this gene fam-(GIBCO BRL, Gaithersburg, MD) supplemented with 10% fetal ily, including survivin (1), have subsequently been identified in bovine serum (FBS). IG10, IF5, Mc6, Pr14, and MOSE cells many species, including humans (2) . Genes for members of the were cultured in Dulbecco's modified Eagle medium (DMEM; LAP family are generally characterized by one or more copies of GIBCO BRL) plus 5% FBS. NIH 3T3 cells were cultured in the so-called baculovirus IAP repeat and by a ring finger domain at their carboxyl terminus (3). The survivin gene, located on the long arm of human chromosome 17 at band 25, contains a single DMEM plus 10% calf serum, and H1299 and HeLa cells were was removed 48 hours after transfection and used to determine cultured in DMEM plus 10% FBS. All media were supple-SEAP activity after normalization of the transfection efficiency. mented with streptomycin (100 pLg/mL), penicillin (100 U/mL), Briefly, the adherent cells were washed once with PBS, exposed glutamine (0.3 mg/mL), and pork insulin (0.25 U/mL or lx ITS to 1 mL of lysis buffer (Promega), and scraped from dishes with [insulin, transferrin, and selenium]; GIBCO BRL, Rockville, a cell scraper. After centrifugation of the cell lysates at 15700 MD). relative centrifugal force (rcf) for 1 minute, the supernatants Western Blot Analysis were removed and stored at -70 'C until luciferase activity was assayed. Luciferase activity was determined by mixing 5 pL of At about 70% confluence, cells were harvested with trypsin/ supernatant with 100 jiL of luciferase assay reagent (Promega) EDTA, and PBS-washed cell pellets were stored at -70 'C until and determining the relative luminescence with a luminometer use. Whole-cell protein was extracted from the cell pellets with (Analytical Luminescence Laboratory, San Diego, CA). This RIPA buffer (50 mM Tris-HCI at pH 7.4, 150 mM NaCl, 1% procedure allowed us to adjust the amount of conditioned meTriton X-100, 0.1% sodium dodecyl sulfate, and 1% sodium dium used to allow for differences in transfection efficiency. deoxycholate). Protein was also extracted from normal tissues (brain, thymus, heart, lung, liver, stomach, small intestine, blad-Stable Transfection der, kidney, ovary, oviduct, uterus, spleen, pancreas, and skeletal muscle) of female C57BL/6 mice (8 weeks, 12 months, or 16 The pSRVN-SEAP-NEO plasmid was linearized with restricmonths of age). Tissues were homogenized in a Mini Bead tion enzyme PvuI and purified by phenol-chloroform extraction monts o ag). Tssus wre hmognizd ina Mni ead and ethanol precipitation. Before electroporation, subconfluent Beater (BioSpec Products, Inc., Bartlesville, OK) and the T-And et l pe re ewectrprtion , s ndlren MER tissue protein extraction reagent (Pierce, Rockford, IL). A2780 cells were trypsinized, washed twice with PBS, and reFor survivin detection, 30 iig of total protein extract was re-suspended at 10 x 106 cells in 0.7 mL of PBS. The cell suspension was transferred into a Gene Pulser cuvette (Bio-Rad Labosolved on sodium dodecyl sulfate-15% polyacrylamide gels and transferred to nitrocellulose membranes (Amersham, Piscata-ratories, Hercules, CA), and 5 aeg of linearized pSRVN-SEAPway, NJ). The blots were hybridized with an anti-survivin poly-NEO or control vector PC3 was added. After 10 minutes on ice, clonal antibody (diluted I:2000; Novus Biological, Littleton, the cells were subjected to electroporation by using the Gene cloal ntiody(diute 1:200; NvusBioogialLitletnPulser II System (Bio-Rad Laboratories) at 250 V/cm and 975 CO), followed by incubation with a peroxidase-conjugated goat Plser pSytem io Laboratrie s at cmpad t7 anti-rabbit second antibody (diluted 1: 5000; Amersham). The meF and then plated in three 10-mm Petri dishes with complete peroxidase activity was detected by the ECL method (NEN,mei.Ondaltr, eiu wschgdtoopee Boston, MA).
growth medium supplemented with G418 at 500 pLg/mL. After 2 weeks, the G418-resistant clones were isolated with cloning cylVector Construction inders. SEAP activity in the conditioned medium from individual clones was determined when the cells were nearly con-SA 1092-base-pair fragment of the human survivin gene pro-fluent.
moter (nucleotides 1821-2912, GenBank accession number U75285) was excised from plasmid SpI with restriction enzymes Animal Study KpnI and XhoI (12) . The secreted alkaline phosphatase (SEAP) expression vector under control of the survivin promoter Female CB 17/ICR SCID (severe combined immunodeficient) (pSRVN-SEAP) was constructed by subcloning the KpnI-XhoI mice, approximately 8 weeks of age and weighing approxifragment into the multiple cloning site of the SEAP expression mately 20 g, were used to establish orthotopic ovarian tumors. vector pSEAP-Basic (Clontech, Palo Alto, CA). To generate All these mice were bred in the Laboratory Animal Facility at stable transfectants, the pSRVN-SEAP-NEO plasmid was con-Fox Chase Cancer Center, were maintained in specific pathogenstructed by subcloning the SRVN-SEAP sequence (a KpnI-XbaI free conditions, and received commercial food and water ad fragment) from pSRVN-SEAP into the PC3 vector (13), a modi-libitum. Institution guidelines were followed in handling the anified pcDNA3 vector (Invitrogen, San Diego, CA) without the mals. To establish the orthotopic tumors, cultured A2780 transcytomegalovirus promoter.
fectants (two SRVN-SEAP-NEO clones, A278OssN1 and Transient Transfection A2780ssN 2 , and one vector control clone, A2780Pc 3 ) were harvested with 0.05% trypsin-EDTA (GIBCO BRL), washed in The pSRVN-SEAP plasmid was transiently transfected into PBS, and resuspended in RPMI-1640 complete medium at 40 x cell lines by use of the TransIT-LT1 transfection reagent (Pan-106 cells per milliliter. Before intrabursal implantation of tumor Vera, Madison, WI). Briefly, 3 x 10 5 cells were placed into each cells, eight SCID mice were anesthetized with a 15 : 3 : 5:152 well of a six-well plate in 2 mL of complete medium. After mixture of ketamine-HC1 (100 mg/mL), acepromazine malleate incubation overnight, cells were 40%-50% confluent, and a (10 mg/mL), xylazine hydrochloride (20 mg/mL) (Fort Dodge mixture of 2 jig of pSRVN-SEAP plasmid, 0.2 jig of pGL3 Animal Health, Fort Dodge, IA), and 0.9% normal saline, incontrol plasmid, 6 jiL of LT1 transfection reagent, and 100 IpL jected intraperitoneally at 10 liL/g of body weight. The skin was of serum-free medium was added to each well. The pGL3 con-disinfected with Wescodyne and 70% ethanol. A small incision trol plasmid (Promega, Madison, WI), which is a luciferase ex-was made on one side of the back to locate the ovary. The pression vector driven by the SV40 promoter, was used to assess oviduct was held with small forceps, and a 26-gauge needle transfection efficiency and, hence, normalize each transfection. connected to a syringe was inserted into the oviduct and was Two other plasmids, pSEAP-Basic (a promoterless SEAP con-passed through the infundibulum until the needle tip reached the struct) and pSV40-SEAP (a SEAP expression vector with the space between the bursa and the ovary. Approximately 20 pIL of SV40 promoter) (Clontech), were also used for each cell line as the cell suspension (about 0.8 x 106 cells) was injected into the negative and positive controls, respectively. Medium (100 pIL) intrabursal space. The needle was slowly removed, the ovary was replaced in the abdominal cavity, and the body wall was measured with a CytoFluor II fluorometer (Bio-Rad Laboratoclosed with sutures. One ovary of each animal was injected.
ries) with excitation and emission wavelengths of 360 nm and Plasma for SEAP analysis was obtained by orbital puncture 449 nm, respectively. SEAP activity was determined from a with heparinized glass tubes (Fisher Scientific, Pittsburgh, PA) standard curve. on days 0, 1, 3, 6, and 9 after cell implantation. About 20 IpL of To determine whether exogenous SEAP could be separated plasma was obtained after the blood was centrifuged at 4500 rcf from endogenous placental alkaline phosphatase of pregnant for 7 minutes (14) . Animals were sacrificed 14 days after im-animals, plasma from two C57BL/6 pregnant mice at embryonic plantation; ovaries were removed, embedded in paraffin, and day 12, one normal control mouse, and one CB17/ICR SCID sectioned for histopathologic analysis.
mouse carrying an A 2 7 80sEAPI3 cell implant (14), was isolated. Five microliters of plasma was mixed with 45 p.L of dilution SEAP Assay buffer, and the mixture was heated to 70 'C for 0, 20, 40, or 60 SEAP activity in culture medium or plasma was determined minutes. Alkaline phosphatase activity was determined as deby a chemiluminescence or fluorescence method using Great scribed above. Escape SEAP kits from Clontech (15) . In brief, 5-1iL samples RESULTS were mixed with 45 p.L of dilution buffer and incubated in a oven at 70 'C for 45 minutes. Sixty microliters of assay buffer Survivin Protein Levels in Cancer Cell Lines, Normal containing L-homoarginine was then added. After a 5-minute Cells, and Normal Tissues incubation at room temperature, the samples were exposed to 60 piL of chemiluminescent substrate CSPD (disodium 3- [4- To determine how frequently the increased expression of sur-
vivin is detected in cancer cell lines compared with normal decan}4-yllphenyl phosphate) (1.25 mM) or 3 piL of fluorescent tissues and cells, protein extracts were prepared from cells and substrate 4-methylumbelliferyl phosphate (Clontech). Chemilu-tissues derived from different species and subjected to western minescence was measured with a luminometer (Analytical Lu-blot analysis. As shown in Fig. 1 , A, survivin protein was deminescence System) after a 10-minute incubation at room tem-tected as an intense band at 16.5 kDa in all the human ovarian perature.
cancer cell lines, including A2780, OVCAR3, OVCAR5, After a 60-minute incubation in the dark, fluorescence was OVCAR8, OVCAR10, SKOV3, PEO1, and UPN251, but not in early-passage normal ROSE and MOSE cells similarly transthe normal HOSE cells. An intense 16.5-kDa survivin band was fected showed less SEAP expression when transfected with also detected in transformed rat ovarian surface epithelial cell pSRVN-SEAP than with pSEAP-Basic (Table 1) . To determine lines (ROSE-TAg, NuTul9, and NuTu26), but only a faint band the relative promoter activity of the survivin promoter compared was detected in early-passage normal ROSE cells ( Fig. 1, B) . with the relatively strong SV40 viral promoter, we transfected Consistent with our findings in normal and transformed ROSE the various cell lines with the SV40 promoter-driven SEAP excells, an intense survivin band was detected in the transformed pression plasmid pSV40-SEAP and measured SEAP expression. MOSE cell lines (IG1O and IF5), but only a faint band was The survivin promoter was more active in the cancer cell lines, detected in the normal MOSE cells (Fig. 1, C ). An intense sur-and the SV40 promoter was more active in the nontransformed vivin band was also detected in tumor cell lines from transgenic cell lines (i.e., NIH 3T3, ROSE, and MOSE cells) ( Table 1 ; mice prone to develop mammary tumors (Mc6) (9) or prostate Fig. 3 ). tumors (Prl4) (10). A faint survivin band was detected in nontumorigenic mouse fibroblast cell line NIH 3T3 (Fig. 1, C ).
Survivin Protein Levels in Normal Adult Mouse Tissues
To determine whether the survivin promoter could induce enough SEAP activity to monitor tumor growth in vivo, we Levels of survivin protein in normal tissues from 8-week-old created stable A2780 transfectants harboring stably integrated female C57BL/6 mice were determined by western blot analysis. SRVN-SEAP-NEO. Two clones (A278OssNl and A2780ssN 2 ) No survivin protein was detected in brain, heart, lung, liver, were selected because of their relatively high SEAP production stomach, intestine, bladder, kidney, ovary, oviduct, uterus, pan- (Fig. 4, A) . These two SRVN-SEAP-NEO clones and one vector creas, or skeletal muscle. Survivin was detected in the thymus control clone (A 2 7 8 0PC
3 ) were used to generate orthotopic ovarand, to a lesser extent, in the spleen (Fig. 2, A) . Because age-ian tumors by injection into the intrabursal space of mouse ovaassociated thymic atrophy could result in a decrease in survivin ries to mimic early ovarian cancer. After tumor cell implantaprotein in the thymus, we evaluated survivin expression in 12-tion, plasma was collected at designated intervals to measure month-old and 16-month-old C57BL/6 mice and detected a SEAP activity. SEAP activity was detected as early as 24 hours marked reduction of survivin protein in mature, as opposed to in animals implanted with 0.8 x 106 cells from either of the two young adult, mice (Fig. 2, B) .
SRVN-SEAP-NEO clones and increased with time and tumor growth. In contrast, SEAP activity was not detected in the aniIn Vitro Survivin Promoter Activity mal injected with the vector control clone (Fig. 4 , B and C).
We constructed the pSRVN-SEAP plasmid to determine Paraffin sections prepared from ovaries removed on day 14 had whether the survivin promoter functioned in cancer cells. Pro-small tumors in the intrabursal cavity in all mice injected with a moter activity was determined from the SEAP activity in con-pSRVN-SEAP-NEO clone (A2780ssN) or the vector control ditioned medium from transiently transfected cells. In A2780 clone (A 2 7 8 0 Pc 3 ) (Fig. 4, D) . Contralateral ovaries were normal. cells transfected with the promoterless pSEAP-Basic plasmid, Sensitivity of Endogenous and Exogenous Alkaline SEAP expression was almost baseline (Table 1) . In several other Phosphatase to Heat Treatment cancer cell lines, SEAP expression was also almost baseline, but in others, the promoterless plasmid had some activity. In all To determine whether endogenous alkaline phosphatase accancer cell lines transfected with a plasmid containing the sur-tivity could be separated from transgenic SEAP activity, we used vivin promoter (i.e., pSRVN-SEAP), SEAP expression was five-heat to inactivate the endogenous activity. Plasma from normal fold to about 400-fold higher than that observed with the pro-control mice, pregnant mice, and a mouse carrying A 2 7 80sEAP13 moterless pSEAP-Basic plasmid (Table 1; Fig. 3, A) . However, cells (14) was treated with heat for 0, 20, 40, or 60 minutes, and , alkaline phosphatase activity in plasma of normal and preg-effector caspases 3, 7, and 9. Survivin, a new member of the nant mice decreased quickly after the heat treatment at 70 'C and human IAP family, was identified by hybridization screening of was still low 40 minutes later. However, plasma alkaline phos-human genomic libraries with the complementrary DNA for phatase activity in the mouse xenografted with A 2 7 8 0SEAP13 effector cell protease receptor-i, a factor Xa receptor (1). Unlike cells had not decreased after 60 minutes of heat treatment, other IAP family members, survivin contains a single baculoviTherefore, exogenous SEAP activity can be monitored during rus IAP repeat and no carboxyl-terminal ring finger region. Most tumor development and effectively separated from endogenous importantly, at variance with other IAPs such as BCL2, which is alkaline phosphatase activity by heat treatment, present in both normal and transformed cell types, survivin was originally reported to be completely undetectable in normal hu-DISCUSSION man adult tissues but expressed during fetal development (1,16,17). Our data on the mouse (this report) and in a published Regulated induction of apoptosis preserves normal homeo-report (18), however, indicate that survivin is present in the stasis and organ morphogenesis. Aberration of this process may thymus and spleen of young adult mice. It seemed unlikely that contribute to cancer development by prolonging cell viability, this difference was related to differences between survivin proMembers of the IAP gene family have emerged as unique modu-moters in mice and humans, because the homology in this region of the mouse and human genes is high (6) . The discrepancy, SEAP expression in ovarian, mammary, colon, lung, and uterine however, could be related to age. Our initial analysis used young cervical cancer cell lines, we have shown that the survivin proadult mice before the onset of thymic atrophy, as did the earlier moter can control gene expression regardless of tumor type, report (18) . Consequently, we investigated whether an age-mechanism of oncogenesis, and species, and we have confirmed related change in survivin expression occurred in the mouse that survivin expression appears to be, at least in part, transcripthymus and found that the level of survivin protein was mark-tionally activated. edly lower in older adult mice than in younger adult mice. In contrast to adult tissues, where survivin expression is A SAGE (serial analysis of gene expression) analysis found largely limited to activation during oncogenesis, in the human that survivin transcripts were the fourth most frequently over-fetus, survivin is abundantly expressed in apoptosis-regulated expressed transcript in common human cancers (e.g., melanoma tissues. Similarly, survivin was nearly ubiquitously expressed in and cancers of the colon, brain, breast, and lung) relative to embryonic mouse tissues at an early gestational stage (embrylevels in normal cells (5) , suggesting that survivin was a poten-onic day 11.5) but was later expressed more selectively (16) . tial target for cancer therapy. If increased survivin activity is Increased survivin expression and survivin promoter activity in controlled transcriptionally, then the survivin promoter might cancer cell lines indicate that transcriptional factors needed for control transgene expression in a cancer-specific manner. Tran-survivin transcription reappear or are reactivated during oncoscriptional regulation of survivin expression in cancer cells has genesis. The approximately 1-kilobase fragment of the survivin indeed been reported (6) . Using approximately 1 kilobase of the promoter used in this study overlaps with the 5' portion of the 5' upstream regulatory region of the survivin gene to drive gene studied by Li and Altieri (6) and contains the CHR (cell it an excellent candidate for these purposes (17, 19) . Finally, we (14) Bao R, Selvakumaran M, Hamilton TC. Use of a surrogate marker (human believe that this cancer-specific reporter gene system could have The tumour suppressor activity of the p53 protein has been Reasoning that p53 functions with one or more mitochondrial facexplained by its ability to induce apoptosis in response to a tors to execute its pro-apoptotic role, we sought to identify p53-bound variety of cellular stresses 1 , 2 . Thus, understanding the mitochondrial proteins. As a source of mitochondrial p53, we used an mechanism by which p53 functions in the execution of cell inducible Saos2 cell line that stably expresses a temperature-sensitive death pathways is of considerable importance in cancer biology.
(ts)-R72 variant of p53 (ref 5). The ts-p53 protein exists in a denaRecent studies have indicated that p53 has a direct signalling tured, inactive, form at 39 'C and becomes wild type in conformation role at mitochondria in the induction of apoptosis 3 -6, although and activity at 32 'C. Importantly, a significant fraction of the p53 prothe mechanisms involved are not completely understood. Here tein localizes to mitochondria after an apoptosis-inducing temperawe show that, after cell stress, p53 interacts with the proture shift to 32 'C (see ref. 5 and Fig. la) . Among several protein bands apoptotic mitochondrial membrane protein Bak. Interaction of that were detectable in mitochondrial p53 immunoprecipitates from p53 with Bak causes oligomerization of Bak and release of cells incubated at 32 'C, but not at 39 6C, was a major species with a cytochrome c from mitochondria. Notably, we show that relative molecular mass (Mr) of approximately 28,000 (Fig. la) . This formation of the p53-Bak complex coincides with loss of an band was excised from SDS-PAGE gels, subjected to tryptic digestion, interaction between Bak and the anti-apoptotic Bcl2-family and the resulting peptides were analysed by liquid chromatography member Mcli. These results are consistent with a model in and tandem mass spectrometry. Two tryptic fragments of the protein which p53 and MclI have opposing effects on mitochondrial Bak were identified (Fig. la) . Bak is a multidomain pro-apoptotic apoptosis by interacting with, and modulating the activity of, member of the Bcl-2 family of proteins, which are key regulators of the death effector Bak.
programmed cell death 8 .We then verified that Bak co-immunoprecipitates with p53 from mitochondrial lysates using immunoprecipitaThe role of p53 in apoptosis is multi-faceted and most probably tion-western blot analysis (Fig. la) . involves its transcriptional regulatory functions, as well as less wellBak is an integral protein of the mitochondrial membrane, and the characterized transcription-independent activities1, 2 . Recent studies R72 form of p53 localizes to mitochondria more effectively than the have demonstrated that a fraction of stress-activated p53 translocates P72 variant. Therefore, we addressed whether these two p53 isoforms to mitochondria after an apoptotic stimulus, but not during would exhibit differences in binding to Bak in vivo that would correp53-dependent growth arrest 3 ' 4 . Further support for the significance late with apoptotic potential. Analysis of whole-cell and mitochondrof p53 mitochondrial localization followed from our analysis of the ial lysates by immunoprecipitation-western blotting confirmed that, apoptotic potential of two polymorphic variants of p53 (ref. 5) . It has compared with P72, much more of the R72 variant is complexed with been known for some time that a common coding region polymor-Bak (Fig. lb, c) . A longer exposure of the autoradiogram detected the phism occurs in human p53, resulting in either an arginine (R72) or less abundant interaction of P72 with Bak (data not shown). In these proline (P72) at amino acid 72. The frequency of the polymorphic analyses, little association was detected between p53 and two other variants of p53 varies in different populations: for example, approxi-Bcl-2 family members, the pro-apoptotic protein Bax and the antimately35--40% of Caucasians, but only 10-12% ofAfricanAmericans, apoptotic protein Bcl-xL, both of which were reported to function in are homozygous for the R72 allele 7 . In an earlier study, we found that mitochondrial apoptosis induction by p53 (refs 4,6) . Similarly, in vitro the R72 variant of p53 exhibits a greater ability to induce apoptosis binding assays using in-vitro-translated proteins identified a robust than does the P72 form, and at least one reason for this difference is association of p53 with Bak, but failed to identify a detectable interacenhanced localization of the R72 variant to mitochondria 5 . The tion of p53 with either Bax or Bcl-xL (Fig. ld) . We extended these greater mitochondrial localization of the R72 variant correlates with studies to verify that the interaction between p53 and Bak occurs in enhanced nuclear export, suggesting that differences in nucleo-cytodifferent cell lines expressing endogenous wild-type p53. assays, protein interactions were examined after solubilization of cellular from ts-P72-Saos2 and ts-R72-Saos2 cells analysed for p53, Bak, Bcl-xL fractions in Chaps, which, unlike non-ionic detergents, does not induce and Bax (left). IP of the same lysates for Bak, Bcl-xL or Bax, followed by an activating, conformational change in Bak or Bax12,3 0 .
cell line MCF7 were treated with camptothecin or ultraviolet irradia-variant in cells 5 . Bak does not bind to the amino-terminal domain tion, respectively, to induce upregulation of p53. (amino acids 1-92), or to the carboxy-terminal domain (amino acids Immunoprecipitation-western blot analysis confirmed that after its 318-393), of p53. Instead, the central region of p53, encompassing stress-induced activation, p53 interacts with Bak (Fig. le) . In these amino acids 92-318, contains the Bak-binding domain (Fig. 2b) . In cells, as with the p53-Saos2 transfectants, a much stronger association fact, these data suggest that there may be two Bak-interacting was detected between p53 and Bak, than between p53 and Bax (Fig. le) domains within the central DNA-binding domain of p53. Other proor Bcl-xL (data not shown).
teins, including mSin3a and TBP, also have been found to interact To map the domain of p53 that interacts with Bak, we used glu-with two distinct regions of the p53 protein 9 ' 0 .We used similar assays tathione S-transferase (GST) pull-down assays, in which 35 S-labelled to map the p53-interacting domain of Bak. These analyses demonin-vitro-translated Bak (full-length) bound to immobilized GST-p53 strated that the introduction of mutations within critical residues of (full-length), but not to GST alone (Fig. 2a) . In these in vitro assays, any of the three Bcl-2-homology regions of Bak (BH1, BH2, BH3) the interaction of the R72 and P72 forms of p53 with Bak was indis-resulted in substantially reduced p53 binding (Fig. 2c) . Existing data tinguishable (Fig. 2a) ; this is consistent with our conclusion that the suggest that these three segments of Bak most probably form a bindgreater association of R72 to Bak observed in vivo (Fig. 1b) reflects the ing pocket that would be disrupted by mutations within any one of enhanced nuclear export and mitochondrial localization of this the domainsl,12. Thus, in vitro binding analysis suggests that p53 LETTERS a b (Bak-I-) mice 18 .Consistent with our results obtained from mitochon-GST-p53 dria purified from cultured human cells, p53 readily induced ,.
• cytochrome c release from mitochondria isolated from wild-type
MEFs. In contrast, incubation with p53 failed to release cytochrome c
35
S-Bak
35 S-BAK --from the Bak-deficient mitochondria (Fig. 3c) . These data further support a model in which p53, operating at the mitochondria, binds directly to Bak, resulting in Bak oligomerization and cytochrome c release. c
To better understand the role of mitochondrial p53 in apoptosis, we Bcl-xL was detected in these assays (Fig. 4b) . A recent report has by 10-20% SDS-PAGE and the autoradiogram was developed, demonstrated that Bak is, in fact, complexed with Mcll in healthy cells 16. We performed in vitro mapping experiments of this interaction interacts directly with Bak through a pocket structure formed by the and determined that an intact BH3 domain of Bak is necessary for an BHI, BH2 and BH3 domains. efficient interaction with MclI (Fig. 4c) . In unstressed cells, Bak is located at the mitochondrial outer memElevated Mcll expression is associated with increased protection brane as an inactive monomer. After diverse apoptotic stimuli, Bak from cell death 2 0 ,
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-2s. We found that in isogenic cell lines with differundergoes an activating conformational change that results in the for-ent levels of Mcli, increased Mcli attenuates Bak oligomerization mation of higher-order multimers; this leads to the release of (Fig. 4d) . These data suggest that Mcli and p53 have opposing roles in cytochrome c and other pro-apoptogenic factors from mitochondria modulating Bak function. Thus, we sought to determine whether the into the cytoso113-1 5 .To assess the ability of p53 to induce oligomeriza-stress-induced activation of p53 alters the Bak-Mcll interaction. For tion of Bak, we used a well-established assay using highly purified these analyses, we took advantage of two well-established cell lines that mitochondria isolated from sucrose gradients 14 ' 15 . The addition of are isogenic, except for their p53 status. The ovarian teratocarcinoma full-length recombinant p53 (R72 or P72) to mitochondria isolated cell line PAl contains wild-type p53. However, its derivative PAl-E6 from unstressed p53-null cells readily shifted Bak from a monomer expresses the human papillomavirus 16 E6 protein, which targets p53 into higher-order multimers (Fig. 3a) . Using deletion mutants of p53, for degradation. It was shown previously 20 ,21 that MclI is a short-lived we confirmed that the ability to bind to Bak correlates positively with protein, and that agents such as ultraviolet irradiation and etoposide their ability to induce Bak oligomerization, as well as to stimulate (which can inhibit new protein synthesis) reduced cellular Mcll levrelease of cytochrome c from purified mitochondria (compare Figs 2b els 
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. As this would interfere with our analyses, we sought stressand 3a). Activation of Bak is accompanied by conformational changes, induction protocols that would not significantly decrease RNA or resulting in the exposure of an amino-terminal epitope of Bak that protein synthesis and Mcli levels. Treatment of cells with the DNAbecomes susceptible to trypsin digestion14, 16, 17 . Therefore, we also damaging agent doxorubicin did not result in decreased steady-state examined whether p53 could induce such a conformational change in levels of Mcll, as illustrated for the PAl and PAi-E6 cells (Fig. 5a) . Bak. First, we confirmed that Bak exists in a relatively inactive trypsin-Notably, induction of p53 by doxorubicin resulted in a significant resistant form in untreated mitochondria (Fig. 3b) . Significantly, incu-decrease in the Bak-Mcll interaction. In PAl-E6 cells lacking p53, bation of mitochondria with recombinant p53, but not GST alone, however, the amount of Mcll co-precipitating with Bak was not resulted in oligomerization of Bak and an increased susceptibility of altered by doxorubicin treatment (Fig. 5a) . Similarly, there was no Bak to trypsin digestion. This enhanced susceptibility to trypsin prote-decrease in cellular Mcll protein abundance in p53-inducible Saos2 olysis was consistent with two different antibodies directed against the cells after temperature shift and apoptosis induction at 32 'C; however, BakN terminus (Fig. 3b) . Together, these data demonstrate that, simi-p53 induction was accompanied by a substantial decrease in the larly to other molecules that activate and oligomerize Bak, p53 induces amount of Mcll complexed to Bak (Fig. 5b) . Thus, p53 activation an amino-terminal conformational change in Bak that is associated results, directly or indirectly, in disruption of the Bak-Mcll complex. with Bak oligomerization. To determine whether p53-induced
The stress-induced localization of p53 to mitochondria is rapid and cytochrome c release is dependent on the ability of p53 to bind and precedes mitochondrial alterations, such as caspase activation and oligomerize Bak, we isolated mitochondria from mouse embryo cytochrome c release3, 4 .Therefore, we assessed whether the interaction fibroblasts (MEFs) derived from wild type (Bak+/+) and Bak-deficient of p53 and Bak correlates temporally with disruption of the Bak-Mcll 
<_4-
Blot: anti-Bak (Ab-1)
4-
Blot: anti-Bak (NT) Bak that is sometimes detected after BMH treatment 14 . In the right panel, mitochondrial fractions from Bakld/ and Bak-l-MEFs were immunoblotted for mitochondria were incubated with 60-100 pmol of the GST-p53-R72 mitochondrial proteins, GRP75 and Bak, and the nuclear-cytoplasmic protein proteins indicated, GST-tBid (positive control for cytochrome c release) or PCNA, demonstrating the integrity of the mitochondrial preparations and GST-Mdm2 (negative control). The supernatant fraction was analysed for absence of contamination from lysed nuclei (left). Mitochondria from Bak+/÷ released cytochrome c by immunoblotting. (b) Mitochondria were incubated in and Bak-1-MEFs were incubated in the presence or absence of GST-p53-R72 the presence or absence of 25 pmol GST-p53, GST alone, or no protein, with (right). Immunoblotting identifies release of cytochrome c from the pellet or without trypsin treatment. Samples were then immunoblotted with antibody fraction to the supernatant in control, but not Bak-deficient, mitochondria. As raised against the Bak N terminus (anti-Bak Ab-1; left). Mitochondria were controls, mitochondrial pellets were immunoblotted for mitochondrial proteins incubated in the presence or absence of 125 pmol GST-p53-R72, with or Bak and Grp75, added recombinant p53, and the nuclear marker Mdm2.
complex. Saos2 cells with inducible p53 were shifted from 39 'C to 32 0 C show that by 6 h, a p53-Bak complex is present, while the Bak-Mcll to activate p53 and to induce apoptosis. At 6 h and 15 h after tempera-complex is no longer detectable despite the fact that mitochondrial Mcll ture shift, cell lysates were immunoprecipitated with an antibody to Bak levels remain unchanged (Fig. 5c) . Notably, loss of the Bak-Mcll cornbefore western blotting for associated p53 or MclI (Fig. 5c) for MclI (Fig. 5e) . Notably, disruption of the Mcll-Bak interaction
correlated with formation of a p53-Bak complex (Fig. 5e ), Bak oligomerization (data not shown) and the release of cytochrome c 0 oq: -from mitochondria (Fig. 5e) . In contrast, incubation of mitochondria 00 
9-
Bak trimer mechanism (in addition to its transcriptional functions) for p53 to Cell lines and purification of mitochondria. H 1299 lungl adenocarcinomaand Saos2 osteosarcoma cells are p53 null. The following human cell lines contain wild-type p53: LNCaP prostate carcinoma (R72); MCF7 breast carcinoma such as Mdm2, caspase-3 and caspase-8, was not detectable at 6 h, but (R72/P72); LoVo colon carcinoma (R72); PAl ovarian teratocarcinoma (R72). was clearly present by 15 h (see Fig. 5c and ref. 5) .Additionally, we found MEF cell lines were established from Bak+/+ and Bak-1 -mice (kindly provided that the p53-Bak complex formed independently of caspase activation, by T. Lindsten and C. Thompson, University of Pennsylvania, Philadelphia, PA). as p53-Bak complexes were detectable even in the presence of the broad-Mitochondria were purified using a differential centrifugation method as spectrum caspase inhibitor zVAD-frnk (Fig. 5d ). These data reinforce described anti-p53
Casp-3 e (10 mM Hepes-KOH at pH 7.4,5 mM KH 2 PO 4 , 5 mM succinate and 250 mM trypsin digestion, and the resulting peptides were analysed by liquid chrosucrose) and resuspended in fractionation buffer B to a final protein concentramatography-tandem mass spectrometry at the Genomics Institute and tion of 2-3 mg m1-1. Protein concentration was determined using the Bradford Abramson Cancer Center Proteomics Core Facility (University of Pennsylvania Reagent (Bio-Rad Laboratories, Inc., Hercules, CA).
School of Medicine, Philadelphia, PA).
Identification of mitochondrial p53-interacting proteins. Mitochondria were Recombinant protein production. Recombinant GST-tagged proteins were purified from the ts-R72 Saos2 cells incubated at 39 0 C or 32 0 C for 22 h and generated using the pGEX-4T-3 vector (Amersham Biosciences, Piscataway, lysed in 1% Chaps Buffer (5 mM MgC1 2 , 137 mM KC1, I mM EDTA, 1 mM NJ), and recombinant His-tagged proteins were produced using pET-32 EGTA, 1% Chaps and 20 mM Tris-HC1 at pH 7.5) supplemented with protease EK/LIC vector (EMD Biosciences). The GST-tagged proteins were induced for inhibitors. For immunopurification, an anti-p53 antibody conjugated to 6 h with 0.1 mM IPTG in BL21 cells doubly deficient for glutathione reductase agarose resin (EMD Biosciences, Inc., Oncogene Research Products, San Diego, and thioredoxin reductase 2 9. His-tagged proteins were induced for 6 h with 0.5 CA) was used. After five washes with 1% Chaps buffer, the associated proteins mM IPTG in BL21 (DE3) cells doubly deficient for glutathione reductase and were resolved by SDS-PAGE in a 10-20% gradient gel (Cambrex Bio Science thioredoxin reductase. For purification of GST-p53, the bacterial pellets were Rockland, Inc., Rockland, ME) and visualized by silver stain (Bio-Rad). The silresuspended in BugBuster HT Extraction Buffer (EMD Biosciences) and ver-stained band corresponding to -28K was excised from the gel, subjected to applied to glutathione-Sepharose 4B (Amersham Biosciences). The Invitrogen) was added to tion assay, 100 jag of mitochondria were incubated with His-thioredoxin, GSTeach reaction, followed by gentle rocking for 30 min at 4 *C. The in vitro binding tBID, His-p53, or GST-p53 at 30 °C for 30 min. The mitochondria were pelleted reactions were washed three times using 1 ml of 0.5% Chaps buffer. GST pullat 10,000g for 15 min, resuspended in 1% Chaps buffer, and immunoprecipidown assays were performed as described 9 . Briefly, 1 jag of GST-p53 fusion protated with an anti-Bak antibody (Upstate) . Protein samples were separated by teins were incubated with 25 jal of 35 S-labelled full-length Bak proteins at 4 'C SDS-PAGE in 10% gels and analysed by western blotting using an anti-Mcll for 30 min with agitation. After brief centrifugation, the beads were washed five antibody (BD Bioscience-Pharmigen) or anti-p53 antibody (EMD Biosciences).
times and resuspended in protein sample buffer. Samples were subjected to SDS-PAGE. To visualize and resolved by SDS-PAGE in 4-20% gradient gels before western blottingwith mtBH2 (Ga7eE, G176E, W177A), Bak mtBH2a (W12 7A, I171A, Gl7SA, an anti-GRP75 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The G176A) and Bak mtBH3 (L78A, D83A) were generated by site-directed mutaremaining 40-RI reaction mixtures were resolved by SDS-PAGE in 4-20% gradient gels and analysed by western blotting using two different antibodies genesis using the QudMChange Site-Directed Mutagenesis Kit System directed against the N terminus of human Bak (anti-Bak NT, Upstate USA; (Stratagene, La Jolla, CA ,. apoptotic potential of the R72 form correlated with its much better ability to traffic to mitochondria. We showed that this enhanced mitochondrial localization of the R72 protein was associated with Nuclear Export increased nuclear export, due to increased binding of R72 to pu3-1172 MDM2, which catalyzes nuclear export of p53. 8 Based on these pE3R 2 data, therefore, we concluded that the enhanced apoptosis-inducing DR72 Active BAK activity of the R72 protein related, at least in part, to its greater MCL1teAK mitochondrial localization. MW BAK MCLl A major question arising from that study centered on defining the apoptotic function of mitochondrial p53. We reasoned that mechanistic insight to this process could be obtained from the iden- Cytosol is a pro-apoptotic member of the BCL2-family of proteins.
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' 26 An analysis of whole cell or mitochondrial extracts by immunoprecipi- Figure 1 . A model for the role of mitochondrial p 5 3 . In response to cell stress tation-western blot analysis, demonstrated that the R72 form of p53 signals, p 5 3 is activated. Relative to the P72 form of p 5 3 , the R72 variant binds better to BAK than does the P72 variant, correlating with the exhibits a greater ability to traffic to mitochondria. Binding of the R72 varidifferences in apoptotic potential of the two p53 variants, ant to pro-apoptotic mitochondrial membrane protein BAK leads to disrupInterestingly, however, our in vitro analyses revealed that the R72 tion of BAK-MCL1 interaction. The formation of a p53-BAK complex induces a conformational change in BAK, BAK oligomerization, and the release of and P72 proteins bind equally well to BAK. These observations are cytochrome c from mitochondria to the cytosol. consistent with the conclusion that the enhanced interaction between BAK and the R72 variant observed in intact cells reflects the enhanced nuclear export and mitochondrial trafficking of this Even more interesting, however, were recent data 32 indicating that p53 isoform.
this anti-apoptotic BCL-2 family member, MCL1, functions as a In healthy cells, BAK resides at mitochondria as an inactive critical upstream regulator of the mitochondrial apoptotic program. monomer. In response to various death stimuli, it undergoes an acti-The downregulation or loss of MCL1 seems to be necessary, albeit vating allosteric conformational change that promotes homo-oligomer-insufficient, to initiate the cell death process, preceding events such ization. This leads to formation of a pore in the outer mitochondrial as BAX/BCL-XL translocation to mitochondria and BAK oligomermembrane, and allows the release of cytochrome c and other ization. In this regard, Cuconati et al. have found that in unstressed pro-apoptogenic factors from the mitochondria resulting in the activa-cells, BAK is complexed with MCL1, and this interaction is lost tion of a caspase cascade. 2 7 -2 9 Having established that stress-activated following adenovirus ElA-initiated apoptosis. 33 We determined that p53 physically interacts with BAK, we then sought to test whether MCL1 is complexed with BAK in normal cells, but that the p53 has the ability to conformationally alter BAK and mediate the stress-induced activation of p53 leads to disruption of the BAKrelease of cytochrome c from mitochondria. In well-established MCL1 complex. 11 Additionally, we demonstrated that formation of assays utilizing purified mitochondria, we determined that p5 3 a p53-BAK complex and concomitant disruption of the BAKbehaved in a manner similar to that of another BAK-interacting MCL1 interaction represent early events in apoptosis that occur protein, tBID, which also catalyzes the oligomerization of BAK. 28 prior to cytochrome c release and caspase activation. Collectively, Specifically, incubation of mitochondria with even nanomolar then, these observations support a model in which the tumor supamounts of recombinant p53 rapidly induced a conformational pressor p53 and the anti-apoptotic MCL1 protein have opposing change in BAK, along with BAK oligomerization and cytochrome c upstream roles in mitochondrial apoptosis: by directly binding to release. Importantly, we showed that p53 requires the presence of mitochondrial BAK, the MCLl and p53 proteins function either to BAK on purified mitochondria in order to induce cytochrome c inhibit or to promote, respectively, BAK's pro-apoptotic behavior release, indicating that p53 is acting through a previously recognized (Fig. 1) . genetic pathway of mitochondrial apoptosis.
The data described above provide new insight into the mechaGiven the discovery that p53 can bind and activate BAK, we nisms involved in an extra-nuclear direct role of p53 in apoptosis sought to elucidate how this interaction might impact on other key induction, binding and oligomerization of BAK. Recently, like BAK, factors that regulate the programmed cell death machinery, the BCL2 family members BAX and BCL-XL have also been impliReasoning that p53 might alter the interaction of BAK with cated in mitochondrial apoptosis induction by p53. 9 ' 1° Employing anti-apoptotic BCL-2 family members, we focused attention on both in vivo and in vitro binding assays, we have detected much less, another mitochondrial protein, MCL1. This decision was based, in if any, association between these proteins and p53. These discrepant part, on previous observations that anti-apoptotic proteins such as results may stem from variations in experimental conditions used by BCL-2 and BCL-XL are not normally present at the mitochondria different groups; indeed, binding conditions must be stringently and do not appreciably interact with BAK in unstressed cells. 30 -32 controlled in such assays, as the conformation and binding activity www.landesbioscience.com Cell Cyclep53 MOVES TO MITOCHONDRIA of BCL-2 family proteins, including BAX and BCL-XL, are known The loss of p53 function directly contributes to tumor progression to be strongly influenced by buffer and detergent conditions.31' 34 and chemoresistance. Thus, restoring key elements of this pathway The biological importance of a p53-BAK interaction is supported by represents an obvious and attractive target for cancer diagnosis and the finding that p53 can efficiently cause cytochrome c release from therapeutics. Approaching this goal, however, requires a clearer isolated mitochondria even if these organelles contain little if any understanding of the mechanisms by which p53 acts in the execution BAX, 9 but cannot do so if these organelles are BAK-deficient.1
